Beckman Coulter has bought its royalty obligations to Nephromics, which covers a preeclampsia test in development. In addition, Beckman Coulter obtained rights to acquire the worldwide diagnostics assets of Nephromics.
Beckman Coulter has began evaluating the preeclampsia product in a clinical trial. The new tests are being designed for detection, monitoring, and risk assessment. The company plans to begin offering the tests by the end of 2009.
The device is undergoing development on the company's family of UniCel® DxI and Access® immunoassay systems as well as UniCel DxCi chemistry-immunoassay work cells.